RAXIBACUMAB (NAT'L STOCKPILE) (raxibacumab)
ANTHRAX MONOCLONAL ANTIBODY · INHALED ANTHRAX ·+1
EMERGENT BIOSOL
Drug class
Anthrax Monoclonal Antibody
An anthrax monoclonal antibody is a targeted biological antitoxin agent, such as raxibacumab or obiltoxaximab, developed for passive immunization against Bacillus anthracis toxicity. Read more about Anthrax Monoclonal Antibody
1 drugs in this class 1 manufacturers
Drugs in Anthrax Monoclonal Antibody
Filter & compare in the drug finder →
Opens the drug finder with Anthrax Monoclonal Antibody preselected. Add indication or manufacturer filters there.
An anthrax monoclonal antibody is a targeted biological antitoxin agent, such as raxibacumab or obiltoxaximab, developed for passive immunization against Bacillus anthracis toxicity.
These agents work by specifically binding to the protective antigen component of the tripartite anthrax toxin, preventing the toxin complex from entering host cells and halting irreversible tissue damage.
Clinically, this drug class is indicated for the treatment of inhalational anthrax in combination with appropriate antibacterial therapy, as well as for post-exposure prophylaxis when alternative treatments are unavailable or unsuitable.
-
fda.gov
An anthrax monoclonal antibody is a targeted biological antitoxin agent, such as raxibacumab or obiltoxaximab, developed for passive immunization against Bacillus anthracis toxicity Clinically, this drug class is indicated for the treatment of inhalational anthrax in combination with appropriate antibacterial therapy, as well as for post-exposure prophylaxis when alternative treatments are unavailable or unsuitable
-
fda.gov
An anthrax monoclonal antibody is a targeted biological antitoxin agent, such as raxibacumab or obiltoxaximab, developed for passive immunization against Bacillus anthracis toxicity These agents work by specifically binding to the protective antigen component of the tripartite anthrax toxin, preventing the toxin complex from entering host cells and halting irreversible tissue damage
-
drugs.com
These agents work by specifically binding to the protective antigen component of the tripartite anthrax toxin, preventing the toxin complex from entering host cells and halting irreversible tissue damage
-
nih.gov
Clinically, this drug class is indicated for the treatment of inhalational anthrax in combination with appropriate antibacterial therapy, as well as for post-exposure prophylaxis when alternative treatments are unavailable or unsuitable
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.